HALO Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of 49.46% compared to Halozyme Therapeutics, Inc.'s net margin of 21.47%. Halozyme Therapeutics, Inc.'s return on equity of 139.43% beat Johnson & Johnson's return on equity of 33.27%.

Halozyme Therapeutics, Inc. has a consensus price target of $77.13, signalling upside risk potential of 6.42%. On the other hand Johnson & Johnson has an analysts' consensus of $212.00 which suggests that it could grow by 3.72%. Given that Halozyme Therapeutics, Inc. has higher upside potential than Johnson & Johnson, analysts believe Halozyme Therapeutics, Inc. is more attractive than Johnson & Johnson.

Halozyme Therapeutics, Inc. has a beta of 0.942, which suggesting that the stock is 5.77% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.341, suggesting its less volatile than the S&P 500 by 65.861%.

Halozyme Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.52% to investors and pays a quarterly dividend of $1.30 per share. Halozyme Therapeutics, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Halozyme Therapeutics, Inc. quarterly revenues are $354.3M, which are smaller than Johnson & Johnson quarterly revenues of $24B. Halozyme Therapeutics, Inc.'s net income of $175.2M is lower than Johnson & Johnson's net income of $5.2B. Notably, Halozyme Therapeutics, Inc.'s price-to-earnings ratio is 15.23x while Johnson & Johnson's PE ratio is 19.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics, Inc. is 7.32x versus 5.38x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of 49.46% compared to Halozyme Therapeutics, Inc.'s net margin of 33.68%. Halozyme Therapeutics, Inc.'s return on equity of 139.43% beat Merck & Co., Inc.'s return on equity of 39.63%.

Halozyme Therapeutics, Inc. has a consensus price target of $77.13, signalling upside risk potential of 6.42%. On the other hand Merck & Co., Inc. has an analysts' consensus of $111.62 which suggests that it could grow by 0.98%. Given that Halozyme Therapeutics, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Halozyme Therapeutics, Inc. is more attractive than Merck & Co., Inc..

Halozyme Therapeutics, Inc. has a beta of 0.942, which suggesting that the stock is 5.77% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.859%.

Halozyme Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 2.97% to investors and pays a quarterly dividend of $0.85 per share. Halozyme Therapeutics, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Halozyme Therapeutics, Inc. quarterly revenues are $354.3M, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Halozyme Therapeutics, Inc.'s net income of $175.2M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Halozyme Therapeutics, Inc.'s price-to-earnings ratio is 15.23x while Merck & Co., Inc.'s PE ratio is 14.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics, Inc. is 7.32x versus 4.36x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Skye Bioscience, Inc. has a net margin of 49.46% compared to Halozyme Therapeutics, Inc.'s net margin of --. Halozyme Therapeutics, Inc.'s return on equity of 139.43% beat Skye Bioscience, Inc.'s return on equity of -91.57%.

Halozyme Therapeutics, Inc. has a consensus price target of $77.13, signalling upside risk potential of 6.42%. On the other hand Skye Bioscience, Inc. has an analysts' consensus of $8.25 which suggests that it could grow by 741.84%. Given that Skye Bioscience, Inc. has higher upside potential than Halozyme Therapeutics, Inc., analysts believe Skye Bioscience, Inc. is more attractive than Halozyme Therapeutics, Inc..

Halozyme Therapeutics, Inc. has a beta of 0.942, which suggesting that the stock is 5.77% less volatile than S&P 500. In comparison Skye Bioscience, Inc. has a beta of 2.680, suggesting its more volatile than the S&P 500 by 168.024%.

Halozyme Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Skye Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Halozyme Therapeutics, Inc. pays -- of its earnings as a dividend. Skye Bioscience, Inc. pays out -- of its earnings as a dividend.

Halozyme Therapeutics, Inc. quarterly revenues are $354.3M, which are larger than Skye Bioscience, Inc. quarterly revenues of --. Halozyme Therapeutics, Inc.'s net income of $175.2M is higher than Skye Bioscience, Inc.'s net income of -$12.8M. Notably, Halozyme Therapeutics, Inc.'s price-to-earnings ratio is 15.23x while Skye Bioscience, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics, Inc. is 7.32x versus 476.49x for Skye Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Stryker Corp. has a net margin of 49.46% compared to Halozyme Therapeutics, Inc.'s net margin of 14.18%. Halozyme Therapeutics, Inc.'s return on equity of 139.43% beat Stryker Corp.'s return on equity of 14.06%.

Halozyme Therapeutics, Inc. has a consensus price target of $77.13, signalling upside risk potential of 6.42%. On the other hand Stryker Corp. has an analysts' consensus of $427.40 which suggests that it could grow by 16.2%. Given that Stryker Corp. has higher upside potential than Halozyme Therapeutics, Inc., analysts believe Stryker Corp. is more attractive than Halozyme Therapeutics, Inc..

Halozyme Therapeutics, Inc. has a beta of 0.942, which suggesting that the stock is 5.77% less volatile than S&P 500. In comparison Stryker Corp. has a beta of 0.890, suggesting its less volatile than the S&P 500 by 10.974%.

Halozyme Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker Corp. offers a yield of 0.93% to investors and pays a quarterly dividend of $0.88 per share. Halozyme Therapeutics, Inc. pays -- of its earnings as a dividend. Stryker Corp. pays out 41.74% of its earnings as a dividend. Stryker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Halozyme Therapeutics, Inc. quarterly revenues are $354.3M, which are smaller than Stryker Corp. quarterly revenues of $6.1B. Halozyme Therapeutics, Inc.'s net income of $175.2M is lower than Stryker Corp.'s net income of $859M. Notably, Halozyme Therapeutics, Inc.'s price-to-earnings ratio is 15.23x while Stryker Corp.'s PE ratio is 48.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics, Inc. is 7.32x versus 5.82x for Stryker Corp.. Usually stocks with elevated PS ratios are considered overvalued.